Thalidomide and Its Analogues Enhance Anti-Tumour Activity of DMXAA
Author Information
Author(s): L-M Ching, WL Browne, R Tchernegovski, T Gregory, BC Baguley, BD Palmer
Primary Institution: Auckland Cancer Society Research Centre, University of Auckland School of Medicine
Hypothesis
Does the inhibition of serum TNF production enhance the anti-tumour activity of DMXAA?
Conclusion
The study suggests that reducing serum TNF levels can improve the anti-tumour effects of DMXAA.
Supporting Evidence
- Thalidomide potentiated the anti-tumour response of DMXAA when administered simultaneously.
- Three analogues of thalidomide were more potent in inhibiting TNF production and enhancing anti-tumour activity.
- Pentoxifylline also suppressed TNF production and increased the anti-tumour effect of DMXAA.
Takeaway
This study found that certain drugs can help a cancer treatment work better by lowering a harmful substance in the body.
Methodology
Mice with Colon 38 tumours were treated with DMXAA and thalidomide or its analogues, and tumour growth was measured.
Limitations
The differences in cure rates were not statistically significant, complicating the assessment of treatment efficacy.
Participant Demographics
C57B1/6 x DBA/2 F1 mice, aged 8-12 weeks.
Want to read the original?
Access the complete publication on the publisher's website